Compare BioNTech SE - ADR (BNTX) vs Super Micro Computer Inc (SMCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Super Micro Computer Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Super Micro Computer Inc trades at $37.25 (market cap $20.44B). The key difference: BioNTech SE - ADR and Super Micro Computer Inc are close in size by market cap, and Super Micro Computer Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SMCI | |
|---|---|---|
Market Cap | $23.31B | $20.44B |
Sector | Health | Technology |
52-Week High | $119.34 | $58.68 |
52-Week Low | $83.89 | $20.53 |
Enterprise Value | $6.60B | $27.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Super Micro Computer (SMCI) surged 18.25% to $37.19 following strong Q4 2026 earnings, beating estimates with $1.70 EPS versus $0.92 expected. The stock shows bullish technical momentum with moving averages supporting upside, while fundamentals reveal robust revenue growth (93% YoY) and expanding margins. Analyst consensus targets $40.40 with 36% buy ratings, though valuation multiples remain reasonable with P/E at 16.63 and P/S at 0.62.
Outlook remains positive driven by AI infrastructure demand and aggressive FY2027 revenue guidance of $65-72B. Key risks include execution on massive backlog, supply chain constraints, and competitive pressures. The stock offers growth exposure but requires monitoring of cash flow trends after 2026 operating cash turned negative amid expansion investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →
